The Sports Bra Expands To Four New Cities Across The United States
Inside The Sports Bra in Portland, Oregon
The Sports Bra
America's original women's sports bar is making big strides across the country.
Today, the Sports Bra announced an expansion from coast to coast, with two major sports cities in between. This follows the September 2024 announcement that, in partnership with Alexis Ohanian, co-founder of Reddit, founding control owner of Angel City FC, and founder of the 776 Foundation, the Sports Bra will franchise nationwide.
The first Sports Bra franchises will open in Boston, Indianapolis, Las Vegas, and St. Louis, all locations with professional womens sports teams. Local fans can cheer on WNBA's Las Vegas Aces and Indiana Fever, the Professional Women's Hockey League's Boston Fleet, the Women's Football Alliance's St. Louis Slam, the Women's National Football Conference's Las Vegas Silver Stars, and the National Women's Soccer League's Boston Legacy FC (set to begin play in the 2026 season).
The Sports Bra opened in Portland in 2022, with a dedication to creating a space to watch women's sports. Since, several independently owned women's sports bars have opened across the country: Rough and Tumble opened in Seattle that same year, A Barof Their Own opened in Minneapolis in 2024, and Watch Me! recently opened in Long Beach, California. Several more women's sports bars are slated to open in 2025, with the count expected to quadruple by year's end.
It's big business according to a report from Barbarian and The GIST, women's sports revenue has seen a 300% increase since 2022, and media coverage of women's sports has increased 275% over the past five years.
'The first four franchises of The Sports Bra will join our OG Portland location to become the 'Starting Five,'' said Nguyen, founder and CEO of The Sports Bra. "Together, we're serving fans nationwide who are hungry for spaces that not only champion women's sports, but create a community where everyone feels like they belong. There is no better moment than this to open these places.'
Each new Sports Bra location will be locally owned and operated, with the aim to will spotlight local producers in each region.
'The Sports Bra is more than just a place to watch the game—it's a movement. Our team spoke with hundreds of interested people about opening a franchise location, and we've met some incredible people along the way,' Nguyen added. "These owner-operators are capable, enthusiastic, and deeply committed to The Bra's mission. We continue to support them as they locate the perfect spaces for their own Bras, and we can't wait to celebrate with them when it's time to open their doors!'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
30 minutes ago
- CNN
Hooters abruptly closes dozens of restaurants
Hooters has abruptly closed dozens of locations just a few months after the chicken wing chain filed for bankruptcy and proclaimed it wasn't 'going anywhere.' 'After careful consideration of what is needed to best position our company for the future, Hooters made the difficult decision to close certain company-owned locations,' a company spokesperson said in a statement to CNN. A specific list of closures wasn't released, but local reports reveal that about 30 locations were affected including several in Florida, Georgia, Michigan, North Carolina, South Carolina, Tennessee and Texas. The company said that it's 'here to stay, and by optimizing our business in support of our long-term goals, Hooters will be well-positioned to continue our iconic legacy under a pure franchise business model.' The 42-year-old chain, best known for its orange-clad, all-female wait staff, filed for bankruptcy in March. Hooters is selling all of its 100 company-owned restaurants to two franchisee groups that operate Hooters locations in the Tampa, Florida, and Chicago areas. However, the closures aren't a complete surprise since the chain said it was 'evaluating the company's operational footprint' for its company-owned locations, which would result in a reduction of its footprint. Hooters also closed dozens of locations prior to bankruptcy in early 2024. Hooters' changes follow the closures of 15 locations of Bahama Breeze, a restaurant chain owned by Darden Restaurants. These chains typically cater to lower and middle-income families looking for a sit-down meal, but diners are abandoning these companies as their disposable income shrinks because of inflation. Consumer sentiment has been free-falling in recent months, and in May remained at a near-record low, according to the University of Michigan's closely watched indicator of how people are feeling about the economy. Closing 'poorly performing units can be better for the chain overall than trying to fix them' because pouring resources into rescuing the those locations can 'undermine the entire chain,' according to Maeve Webster, president of consulting firm Menu Matters. 'It's similar to rationalizing a menu: Better to eliminate items that aren't selling or rarely selling to improve the quality and consistency of what remains,' she recently told CNN. TGI Fridays, which aims to exit bankruptcy this summer, has also gradually closed locations while it navigates Chapter 11. The chain recently relaunched its menu for its remaining 85 US locations in hopes of sparking people's attention .
Associated Press
an hour ago
- Associated Press
Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis
First-in-class agent targets WISP1 in patients with IPF Primary endpoint in WISPer trial is change in Forced Vital Capacity (FVC) at 24 Weeks BOSTON, June 5, 2025 /PRNewswire/ -- Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has been dosed in its Phase 2 WISPer clinical trial evaluating MTX-463, an investigational therapy for idiopathic pulmonary fibrosis (IPF). The study's primary endpoint is the change from baseline in forced vital capacity (FVC)—an important measure of lung function—at 24 weeks. The study aims to advance the development of a potential novel treatment for patients living with IPF, and targets the myofibroblast, the key pathogenic cell in fibrosis. Mediar recently entered into a global licensing agreement with Lilly to advance MTX-463 through the Phase 2 WISPer trial. IPF is a rare and progressive lung disease characterized by scarring and thickening of lung tissue, which leads to increasing shortness of breath and a persistent dry cough. Despite available treatments, there remains a high unmet medical need, with an average life expectancy of three to five years post-diagnosis. The WISPer trial is a randomized, double-blind, placebo-controlled 24-week Phase 2 study designed to evaluate the efficacy, safety, and tolerability of MTX-463 in patients living with IPF. 'Dosing the first patient in the WISPer trial represents an important step forward in the pursuit of new options to address the urgent needs of individuals living with IPF,' said Toby Maher, MD, PhD, Director of Interstitial Lung Disease, University of Southern California, and lead investigator in the Phase 2 clinical study. 'IPF is a devastating disease with limited treatment options. We are eager to evaluate the potential of MTX-463 to slow or halt disease progression and look forward to the insights this study will provide for patients and their physicians.' 'Today marks an important milestone in our ongoing commitment to pioneering novel therapies to impact people living with fibrotic diseases. We extend our gratitude to Dr. Ryan Klein and the dedicated team at NewportNativeMD whose expertise and collaboration have been instrumental in reaching this important step,' said Jeff Bornstein, MD, Chief Medical Officer, Mediar. 'The first patient dosed with this first-in-class anti-fibrotic marks the beginning of a new chapter in our research, and we look forward to working with our clinical sites as we continue to enroll the Phase 2 program.' Mediar is also independently advancing its two wholly owned programs to treat other fibrotic disorders. MTX-474, a first-in-class human IgG1 antibody designed to neutralize EphrinB2 signaling, recently completed its Phase 1 clinical study. Mediar anticipates initiating a Phase 2 trial for MTX-474 in systemic sclerosis in the second half of 2025. Mediar's third novel fibrosis program, targeting SMOC2 for renal fibrosis, is also advancing with a plan to nominate a clinical candidate in the first half of 2025. About MTX-463 MTX-463 is a first-in-class human IgG1 antibody developed against WNT1-inducible signaling pathway protein-1 (WISP1). WISP1 is a secreted matricellular protein shown to have a relevant role in fibrosis progression, is measurable in human blood, and correlates with disease severity. Data indicates that MTX-463 neutralizes WISP1-mediated fibrotic signaling and significantly reduced fibrosis in vitro and in various preclinical models. A Phase 1 study was recently completed and a Phase 2 study in patients with IPF is now open (NCT06967805). More information can be found at: About Mediar Therapeutics Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar's goal is to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach. For more information, contact [email protected] or follow us on LinkedIn. Media Contact [email protected] View original content to download multimedia: SOURCE Mediar Therapeutics
Yahoo
an hour ago
- Yahoo
The Joint Corp. Announces $5 Million Stock Repurchase Program
SCOTTSDALE, Ariz., June 05, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, announced that its board of directors has authorized a stock repurchase program expected to begin in August 2025 under which the company may repurchase up to $5 million of its outstanding common stock. 'The stock buyback reflects the board's confidence in our long-term strategy, refranchising program and our projected cash flow generation,' said Sanjiv Razdan, chief executive officer, president and director of The Joint Corp. 'We believe our franchise model and long-term valuation are not yet fully recognized in our current stock price. This stock repurchase program underscores our commitment to disciplined capital allocation and delivering value to our stockholders.' Repurchases may be made from time to time in open market transactions, privately negotiated transactions, or by other means, in accordance with applicable securities laws and subject to market conditions and other factors. The timing, number and amount of any repurchases will be determined by the company's finance committee of the board of directors at its discretion. The stock repurchase program does not obligate the company to acquire any particular amount of common stock, has a termination date of June 3, 2027 and may be suspended or discontinued at any time. About The Joint Corp. (NASDAQ: JYNT) The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation's largest operator, manager and franchisor of chiropractic clinics through The Joint Chiropractic network. The company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. Headquartered in Scottsdale, with over 950 locations nationwide and more than 14 million patient visits annually, The Joint Chiropractic is a key leader in the chiropractic industry. The brand is consistently named to Franchise Times' annual 'Top 400' and 'Fast & Serious' list of 40 smartest growing brands. Entrepreneur named The Joint 'No. 1 in Chiropractic Services,' and is regularly ranked on the publication's 'Franchise 500,' the 'Fastest-Growing Franchises,' the 'Best of the Best' lists, as well as its 'Top Franchise for Veterans' and 'Top Brands for Multi-Unit Owners.' SUCCESS named the company as one of the 'Top 50 Franchises' in 2024. The Joint Chiropractic is an innovative force, where healthcare meets retail. For more information, visit To learn about franchise opportunities, visit Business Structure The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Tennessee, Washington, and West Virginia, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices. Forward-Looking Statements This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. Specific forward-looking statements made in this press release include, among others, our belief that the stock buyback reflects the board's confidence in our long-term strategy, refranchising program and our projected cash flow generation; that our franchise model and long-term valuation are not yet fully recognized in our current stock price, and that the stock repurchase program underscores our commitment to disciplined capital allocation and delivering value to our stockholders. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage and an increase in operating expenses due to measures we may need to take to address such shortage; inflation, which has increased our costs and which could otherwise negatively impact our business; our failure to profitably operate company-owned or managed clinics; our failure to refranchise as planned; short-selling strategies and negative opinions posted on the internet, which could drive down the market price of our common stock and result in class action lawsuits; our failure to remediate future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence; and other factors described in our filings with the SEC, including in the section entitled 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 14, 2025 and subsequently filed current and quarterly reports. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data. Media Contact:Margie Wojciechowski, The Joint Corp., Investor Contact:Kirsten Chapman, Alliance Advisors IR, 415-433-3777, thejointinvestor@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
